Therapeutic focus » The PharmNovo Journey

From safety to efficacy

HAVING FINALISED our first in man trials. Our aim is to establish efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2024.

Prior to 2020

Establishing the baseline

  • Founding PharmNovo
  • PN6047 discovered
  • Convincing pre-clinical efficacy data
  • Patent applications in major markets

Setting the scene

  • GMP compound production and process development
  • Toxicology studies to support clinical studies
  • Phase I - first in human trials
  • Secure patent protection in all major markets


  • Establishing efficacy and defining path to market
  • Phase IIA PoC efficacy studies in one or more patient populations
  • Identification of VC/Pharma partner
  • Alignment of path to market with regulatory authorities, in particular EMA and FDA

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more